(Q37151336)

18 August 2017

1 reference

title

Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates (English)

1 reference

18 August 2017

0 references

Amber E King

1

1 reference

18 August 2017

Elena M Umland

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

28

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

667-677

1 reference

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaw associated with pamidronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaws associated with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Exposed bone in oral cavities

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Clinical update: a nonhealing fractured mandible

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaw and oral bisphosphonate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Implications of androgen-deprivation therapy in patients with prostate cancer: A case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

The dental implications of bisphosphonates and bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.667

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.5.667

1 reference

18 August 2017

1 reference